硼替佐米治疗的多发性骨髓瘤患者中的急性肾损伤
本研究在单中心回顾性分析2006至2017年276例首次接受硼替佐米为基础化疗的多发性骨髓瘤患者,急性肾损伤发生率为17%(47例),实验室肿瘤溶解综合征发生率为13%(36例),仅10例(3.6%)同时符合两者标准;多因素分析显示较低eGFR、较低血清白蛋白、肾淀粉样变及合用阿昔洛韦是急性肾损伤的预测因素。
要点
- 硼替佐米化疗后急性肾损伤发生率17%,实验室肿瘤溶解综合征发生率13%,仅3.6%两者并存。
- 急性肾损伤的预测因素包括较低eGFR、低白蛋白、肾淀粉样变及合用阿昔洛韦。
- 肿瘤溶解综合征风险与较高β-2微球蛋白及无高危染色体异常相关。
核心结论
- 多发性骨髓瘤患者接受硼替佐米治疗后,急性肾损伤常在无肿瘤溶解综合征的情况下发生,且两者的危险因素差异很大,提示硼替佐米在肾功能下降患者中可能存在不依赖肿瘤溶解综合征的潜在肾毒性。
研究设计与样本
- 单中心回顾性研究,纳入2006年至2017年首次接受硼替佐米为基础化疗的多发性骨髓瘤患者276例。
- 实验室肿瘤溶解综合征按Cairo-Bishop定义判定,急性肾损伤按AKI网络标准在首次化疗后7天内评估。
主要发现
- 中位年龄65(56-72)岁,基线eGFR为61.3(34.1-89.1)mL/min/1.73 m2。
- 急性肾损伤发生率为17%(n=47),实验室肿瘤溶解综合征发生率为13%(n=36),10例(3.6%)同时符合两者标准。
- 多因素分析显示,以eGFR≥60为参照,eGFR 30-59的OR为3.005(95%CI 1.163-7.976),15-29的OR为4.225(95%CI 1.183-15.000),<15的OR为16.154(95%CI 3.831-70.920),P<.001。
- 血清白蛋白每升高1单位,急性肾损伤OR为0.479(95%CI 0.256-0.871),P=.018;肾淀粉样变OR为13.039(95%CI 4.108-44.041),P<.001;硼替佐米治疗期间使用阿昔洛韦OR为3.689(95%CI 1.133-14.469),P=.042。
- 肿瘤溶解综合征的多因素分析中,β-2微球蛋白OR为1.204(95%CI 1.005-1.461),P=.038;无高危染色体异常OR为0.143(95%CI 0.022-0.588),P=.016。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The nephrotoxicity of bortezomib, a proteasome inhibitor, has not yet been elucidated, although tumor lysis syndrome (TLS) associated with multiple myeloma (MM) has been reported to increase after introduction of the drug. This study compared the incidence and risk factors for acute kidney injury (AKI) and TLS in patients with MM after bortezomib-based chemotherapy to investigate drug-related nephrotoxicity. METHODS: From 2006 to 2017, 276 patients who underwent a first cycle of bortezomib-based chemotherapy for MM were identified in a single tertiary hospital. Laboratory TLS was defined according to the Cairo-Bishop definition. Development of AKI was assessed by AKI Network criteria within 7 days of the first chemotherapy. RESULTS: The median (interquartile range) age was 65 (56-72) years, and baseline estimated glomerular filtration rate (eGFR) was 61.3 (34.1-89.1) mL/min/1.73 m2. The incidences of AKI and laboratory TLS were 17% (n = 47) and 13% (n = 36), respectively. Ten (3.6%) subjects met both AKI and TLS criteria. Multivariate analyses showed that lower eGFR category [30-59, odds ratio (OR) 3.005 (95% confidence interval 1.163-7.976); 15-29, OR 4.225 (1.183-15.000); <15, OR 16.154 (3.831-70.920) vs ≥60, P < .001], lower serum albumin level [per 1 increase, OR 0.479 (0.256-0.871), P = .018], renal amyloidosis [OR 13.039 (4.108-44.041), P < .001] and use of acyclovir during bortezomib treatment [OR 3.689 (1.133-14.469), P = .042] were predictors of AKI. MM stages and β-2-microglobulin were not associated with increased risk of AKI. Regarding laboratory TLS, MM stage and β-2-microglobulin were higher in those with TLS than in others. In multivariate analyses, β-2-microglobulin level [OR 1.204 (1.005-1.461), P = .038] and absence of high-risk chromosome abnormalities [OR 0.143 (0.022-0.588), P = .016] were associated with higher risk of TLS. CONCLUSIONS: Development of AKI was often observed in the absence of TLS in patients with MM after treatment with bortezomib. In addition, the risk factors for AKI and TLS varied widely. These findings indicate the potential nephrotoxicity of bortezomib irrespective of TLS in patients with decreased kidney function.
引用
- Song SM, Jeon J, Jang HR, et al. Acute kidney injury in bortezomib-treated patients with multiple myeloma. Nephrol Dial Transplant. 2023. PMID: 36662030. doi:10.1093/ndt/gfad016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。